Filtered By:
Specialty: Hematology
Condition: Hemorrhagic Stroke
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 295 results found since Jan 2013.
Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12795. doi: 10.1002/rth2.12795. eCollection 2022 Aug.ABSTRACTIntravenous thrombolysis is a standard of care treatment for patients with acute ischemic stroke. Tissue plasminogen activator (tPA) has been the main thrombolytic agent used since the publication of the seminal National Institutes of Neurological Disorders and Stroke trial in 1995. There is now mounting evidence to support the routine use of Tenecteplase (TNK) to treat acute ischemic stroke. TNK is a genetically modified tPA with higher fibrin specificity, longer half-life, and reduced systemic coagulopathy. In this il...
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Annie Zhu Phavalan Rajendram Eric Tseng Shelagh B Coutts Amy Y X Yu Source Type: research
Viscoelastic Testing in the Clinical Management of Subarachnoid Hemorrhage and Intracerebral Hemorrhage
In conclusion, viscoelastic testing suggests hypercoagulation following SAH and ICH. Further investigation of the predictive value of increased clot firmness in SAH seems relevant. In ICH, the prediction of hematoma expansion and ICH as a complication to thrombolysis might be clinically relevant. [...] Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents | Abstract | Full text
Source: Seminars in Thrombosis and Hemostasis - September 13, 2022 Category: Hematology Authors: Hvas, Christine Lodberg Hvas, Anne-Mette Tags: Review Article Source Type: research
Predictors of symptomatic intracranial hemorrhage after endovascular treatment for acute large vessel occlusion: data from ANGEL-ACT registry
AbstractSymptomatic intracranial hemorrhage (SICH) is a catastrophic complication of endovascular treatment (EVT) for large vessel occlusion (LVO). We aimed to investigate the incidence and predictors of SICH after EVT. Patients were selected from the ANGEL-ACT registry. We diagnosed SICH according to the Heidelberg Bleeding Classification. Logistic regression analyses were performed to determine the independent predictors of SICH. Of the 1283 patients, SICH was observed in 116 patients (9.0%). On multivariable analysis, admission National Institutes of Health Stroke Scale (NIHSS) > 12 (odds ratio [OR] = 1.86,...
Source: Journal of Thrombosis and Thrombolysis - August 1, 2022 Category: Hematology Source Type: research
Association of coagulation factors profile with clinical outcome in patient with COVID-19 and acute stroke: A second wave cohort study
This study reported coagulation profile of COVID-19 patients with acute stroke and its association with patients' outcome.METHOD: This is a cohort-retrospective study conducted during the second wave of COVID-19, June-August 2021 in Cipto Mangunkusumo General Hospital. Inclusion criteria were adult patients with confirmed COVID-19 and diagnosed with acute stroke confirmed by radiological evidences. Exclusion criteria were COVID-19 patients with prior diagnosis of acute stroke. Coagulation factors were analyzed and presented with tables and graphs.RESULTS: A total of 33 patients included in this study with majority experien...
Source: Clinical Hemorheology and Microcirculation - July 24, 2022 Category: Hematology Authors: Al Rasyid Dinda Larastika Riyanto Salim Harris Mohammad Kurniawan Taufik Mesiano Rakhmat Hidayat Elvan Wiyarta Source Type: research
Pre-admission antithrombotic use is associated with 3-month mRS score after thrombectomy for acute ischemic stroke
AbstractIn patients who undergo thrombectomy for acute ischemic stroke, the relationship between pre-admission antithrombotic (anticoagulation or antiplatelet) use and both radiographic and functional outcome is not well understood. We sought to explore the relationship between pre-admission antithrombotic use in patients who underwent thrombectomy for acute ischemic stroke at two medical centers in New York City between December 2018 and November 2020. Analyses were performed using analysis of variance and Pearson ’s chi-squared tests. Of 234 patients in the analysis cohort, 65 (28%) were on anticoagulation, 64 (27%) we...
Source: Journal of Thrombosis and Thrombolysis - July 21, 2022 Category: Hematology Source Type: research
Over-transfusion with blood for suspected hemorrhagic shock is not associated with worse clinical outcomes
DISCUSSION: Early empiric RBC transfusion for presumed hemorrhagic shock may subject patients to potential over-transfusion and end-organ damage. Among patients meeting clinical triggers for MTP, 1-3 units of allogeneic RBCs is not associated with worse outcomes.PMID:35753037 | DOI:10.1111/trf.16978
Source: Transfusion - June 26, 2022 Category: Hematology Authors: Rondi B Gelbard Russell L Griffin Lindy Reynolds Peter Abraham Jeffrey Warner Parker Hu Jeffrey D Kerby Rindi Uhlich Marisa B Marques Jan O Jansen John B Holcomb Source Type: research
Intravenous thrombolysis and endovascular thrombectomy for acute ischaemic stroke in patients with Moyamoya disease - a systematic review and meta-summary of case reports
ConclusionsIn this systematic review and meta-summary, the utility of IVT and ET in MMD-associated AIS appears feasible in selected cases. Further larger cohort studies are required to evaluate these treatment approaches.Highlights· AIS in MMD was typically managed with bypass surgery but not via thrombolysis or thrombectomy.· In this meta-summary, all patients treated with thrombolysis and/or thrombectomy survived and some experienced symptomatic and/or functional improvement.· Further larger cohort studies are necessary for investigating the role of thrombolysis and/or thrombectomy as treatment of AIS in MMD.
Source: Journal of Thrombosis and Thrombolysis - June 14, 2022 Category: Hematology Source Type: research
Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings
CONCLUSION: In patients with AF, stable CAD, and preserved renal function, rivaroxaban underdose was associated with similar rates of thrombotic events but a lower incidence of hemorrhagic events than the standard dose.CLINICAL TRIAL REGISTRATION: AFIRE UMIN Clinical Trials Registry (https://www.umin.ac.jp/ctr/), number UMIN000016612, and ClinicalTrials.gov, number NCT02642419.PMID:35697255 | DOI:10.1055/s-0042-1744543
Source: Thrombosis and Haemostasis - June 13, 2022 Category: Hematology Authors: Hiroyuki Arashi Junichi Yamaguchi Nobuhisa Hagiwara Satoshi Yasuda Koichi Kaikita Masaharu Akao Junya Ako Tetsuya Matoba Masato Nakamura Katsumi Miyauchi Kazuo Kimura Atsushi Hirayama Kunihiko Matsui Hisao Ogawa Source Type: research
